Fibromyalgia, gout, osteoarthritis, and rheumatoid arthritis are some of the most important causes of suffering, disability and early retirement in the world.
However, technological innovations over the past decade have transformed the understanding and treatment of the broad spectrum of rheumatic diseases. Since the first anti-TNFα, advances in biologic disease-modifying anti-rheumatic drugs (DMARDs) have revolutionized patient treatment. At the same time, payers are facing the challenge of an increase in drug expenditures.
The recent introduction of biosimilars aims to offer new solutions at a lower cost, but it raises other questions related to switching and interchangeability. Additionally, drugs with new mechanisms of action are being developed, such as anti-IL6, anti-IL12/IL-23, and JAK-1/JAK-2 inhibitors.
We are committed to biopharmaceutical, medical device and diagnostic development in order to optimize the possibility of success. As a full-service CRO, Eurotrials can handle the clinical and operational issues involved in the clinical development of biologic products.
With more than 20 years of experience in the industry, our multidisciplinary team includes medical, operational, strategy and regulatory specialists, as well as market access experts who plan and implement worldwide studies, guiding you and providing you strategic support in every step of the product lifecycle.
Long-term relationships with medical and scientific leaders and research centers in Europe and Latin America contribute to valued expert input for your projects from project design to patient engagement.